Dogwood Therapeutics Stock Rallies 35% On Serpin Pharma Licensing Deal

(RTTNews) - Dogwood Therapeutics, Inc. (DWTX) jumped 34.78 percent to $7.44 on Monday, up $1.92, after announcing it secured a royalty-free, global license to develop Serpin Pharma's IV formulation of SP16 for managing cancer-related pain and chemotherapy-induced neuropathy. The forthcoming Phase 1b trial of SP16 IV is fully funded by the National Cancer Institute. The stock opened at $8.41 and traded between $7.07 and $9.50, compared with a previous close of $5.52 on the Nasdaq. Trading volume surged to 41.7 million shares, well above the average of 19,600. The stock now trades within a 52-week range of $1.62 to $29.28.